Tolfedine 6 mg tablets

Country: Írland

Tungumál: enska

Heimild: HPRA (Health Products Regulatory Authority)

Virkt innihaldsefni:

Tolfenamic acid

Fáanlegur frá:

Vetoquinol Ireland Limited

ATC númer:

QM01AG02

INN (Alþjóðlegt nafn):

Tolfenamic acid

Skammtar:

6 mg/tablet

Lyfjaform:

Tablet

Gerð lyfseðils:

POM: Prescription Only Medicine as defined in relevant national legislation

Meðferðarhópur:

Canine, Feline

Lækningarsvæði:

tolfenamic acid

Ábendingar:

N.S.A.I.D.

Leyfisstaða:

Authorised

Leyfisdagur:

1993-08-12

Vara einkenni

Health Products Regulatory Authority
06 November 2018
CRN008PTT
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Tolfedine 6 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Tablet contains:
Active Substance:
Tolfenamic Acid 6 mg
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs, Cats
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cat: Febrile syndromes (abscess, fever of unknown origin)Dog: Acute
flare ups of
chronic locomotor disease
4.3 CONTRAINDICATIONS
Concurrent administration with other steroidal or non-steroidal
anti-inflammatory
drugs.
Do not use in animals with suspected gastro-duodenal ulceration.
Do not use in animals with impaired renal or hepatic function.Do not
use in pregnant
animals.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTION(S) FOR USE IN ANIMALS
Health Products Regulatory Authority
06 November 2018
CRN008PTT
Page 2 of 5
Do not exceed the stated dose or duration of treatment.
Use in any animal less than 6 weeks of age or in aged animals may
involve additional
risk. If such use cannot be avoided, careful clinical management is
essential. Reduced
metabolism and excretion in these animals should be considered.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as
there is a
potential risk of increased renal toxicity.
It is preferable that TOLFEDINE is not administered to animals
undergoing general
anaesthesia until fully recovered.
Where there is appearance of bloody or black faeces, a veterinary
surgeon should be
contacted for advice and the possibility of stopping treatment should
be considered.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Diarrhoea and vomiting may occur during treatment. Where either
persists,
treatment should be discontinued.
4.7 USE DURING PREGNANCY, LACTATION O